Inclusion Criteria:  Patients with colorectal cancer confirmed by pathological tissue or cytology； The pathological type of colorectal tumor was adenocarcinoma； Patients with recurrent or metastatic, unresectable advanced colorectal cancer； Patients who received regorafenib at least one period treatment.  Exclusion Criteria:  Patients participating in other interventional clinical studies while taking regorafenib; Patients with other malignant tumors within 5 years before regorafenib treatment, except for cured cervical carcinoma in situ, skin squamous cell carcinoma or basal cell carcinoma, early papillary thyroid carcinoma, etc.; The investigator deems that there are other factors that are not suitable for patients who participate in this study.